Background
Methods
Data sources
Search | Query | Items found |
---|---|---|
#1 | “eldecalcitol”[Supplementary Concept] OR “eldecalcitol”[All Fields] | 177 |
#2 | (“diphosphonates”[MeSH Terms] OR “diphosphonates”[All Fields] OR “bisphosphonate”[All Fields]) OR “diphosphonate”[All Fields]) OR “bisphosphonates”[All Fields]) OR Bisphosphate[All Fields] OR (“alendronate”[MeSH Terms] OR “alendronate”[All Fields]) OR (“pamidronate”[MeSH Terms] OR “pamidronate”[All Fields]) OR “zoledronic acid”[All Fields] OR (“ibandronic acid”[MeSH Terms] OR (“ibandronic”[All Fields] AND “acid”[All Fields]) OR “ibandronic acid”[All Fields] OR “ibandronate”[All Fields]) OR (“risedronic acid”[MeSH Terms] OR (“risedronic”[All Fields] AND “acid”[All Fields]) OR “risedronic acid”[All Fields] OR “risedronate”[All Fields]) OR (“clodronic acid”[MeSH Terms] OR (“clodronic”[All Fields] AND “acid”[All Fields]) OR “clodronic acid”[All Fields] OR “clodronate”[All Fields]) OR (“YM 529”[Supplementary Concept] OR “YM 529”[All Fields] OR “minodronate”[All Fields]) OR (“3-(2,2,2-trimethylhydrazine)propionate”[Supplementary Concept] OR “3-(2,2,2-trimethylhydrazine)propionate”[All Fields] OR “mildronate”[All Fields]) | 57,670 |
#3 | “osteoporosis, postmenopausal”[MeSH Terms] OR (“osteoporosis”[All Fields] AND “postmenopausal”[All Fields]) OR “postmenopausal osteoporosis”[All Fields] OR “osteoporosis”[All Fields] OR “osteoporosis”[MeSH Terms] | 87,049 |
#4 | #1 AND #2 AND 3 | 33 |
Inclusion and exclusion criteria
Data extraction and quality assessment
Statistical analysis
Results
Included studies
Study | Area | Design | Duration | Criteria for osteoporosis | Duration | Group | Intervention | n | Age, years | Women, n (%) | BMI |
---|---|---|---|---|---|---|---|---|---|---|---|
Ebina et al. [28] | Japan | Non-RCT | NR | JSBMR | 12 months | BP + ELD | MIN 50 mg/month, ELD 0.75 μg/day | 80 | 71.8 ± 0.9 | 74 (92.5%) | 21.3 ± 0.6 |
BP | MIN 50 mg/month | 63 | 71.7 ± 1.6 | 58 (92.1%) | 21.5 ± 0.6 | ||||||
Iwamoto and Sato [23] | Japan | RCT | April 2012–July 2012 | JDC | 6 months | BP + ELD | ALE 35 mg weekly or risedronate 17.5 mg weekly, ELD 0.75 μg/day | 50 | 72.3 ± 8.3 | 50 (100%) | 22.5 ± 3.3 |
BP | ALE 35 mg weekly or risedronate 17.5 mg weekly | 46 | 69.1 ± 9.9 | 46 (100%) | 22.7 ± 2.5 | ||||||
Suzuki et al. [29] | Japan | RCT | May 2016–August 2017 | JSBMR | 18 months | BP + ELD | MIN 50 mg/month, ELD 0.75 μg/day | 14 | 68.7 ± 3.1 | 14 (100%) | 20.4 ± 0.7 |
BP | MIN 50 mg/month | 14 | 65.8 ± 4.0 | 14 (100%) | 20.1 ± 0.5 | ||||||
Takeuchi et al. [27] | Japan | Non-RCT | March 2014–January 2017 | JDC | 12 months | BP + ELD | Ibandronate 1 mg injections, ELD NR | 94 | NR | NR | NR |
BP | Ibandronate 1 mg injections | 95 | NR | NR | NR |